Free Newsletter
Emergent gets $404M vaccine contract
It seems that hardly a week goes by in which Emergent Biosolutions doesn't get a vaccine contract. This week it's a $404 million contract with the U.S. government to provide 14.5 million doses of BioThrax anthrax vaccine. The new contract is an extension of company's current $448 million contract to supply 18.75 million doses of the vaccine. First deliveries of BioThrax under this new contract are scheduled to begin in the third quarter of 2009, when the old contract expires.
"We are encouraged that we were able to secure this new procurement for an additional 14.5 million doses with HHS, because it represents a seamless transition from our current contract for the shipment of 18.75 million doses of BioThrax into the SNS," said Fuad El-Hibri, chairman and CEO of Emergent.
- here's Emergent's release
Related Articles:
Emergent inks $29.7M anthrax vax contract
Emergent wins $24M anthrax contract
VaxGen sells anthrax vaccine to Emergent
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A; Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
More Research Reports >>
